Glenmede Trust Co. NA Buys 62,034 Shares of Zoetis Inc. $ZTS

Glenmede Trust Co. NA lifted its stake in shares of Zoetis Inc. (NYSE:ZTS) by 36.5% in the first quarter, according to its most recent filing with the SEC. The fund owned 231,874 shares of the company’s stock after acquiring an additional 62,034 shares during the period. Glenmede Trust Co. NA’s holdings in Zoetis were worth $27,410,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ZTS. Vanguard Group Inc. raised its position in Zoetis by 12.9% during the fourth quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company’s stock valued at $6,011,802,000 after purchasing an additional 5,474,210 shares in the last quarter. J. Stern & Co. LLP boosted its holdings in shares of Zoetis by 12,431.2% in the 4th quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company’s stock worth $3,028,423,000 after purchasing an additional 23,877,416 shares in the last quarter. State Street Corp increased its position in shares of Zoetis by 0.8% during the 4th quarter. State Street Corp now owns 19,796,891 shares of the company’s stock valued at $2,490,845,000 after purchasing an additional 149,382 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Zoetis by 1.7% during the 4th quarter. Geode Capital Management LLC now owns 11,327,679 shares of the company’s stock valued at $1,420,294,000 after purchasing an additional 189,235 shares during the last quarter. Finally, Norges Bank purchased a new position in shares of Zoetis during the 4th quarter valued at about $734,425,000. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have issued reports on ZTS. UBS Group cut their target price on Zoetis from $99.00 to $85.00 and set a “neutral” rating for the company in a research note on Monday, July 27th. Weiss Ratings downgraded shares of Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, June 12th. Stifel Nicolaus lowered their price objective on shares of Zoetis from $95.00 to $85.00 and set a “hold” rating for the company in a report on Friday, June 26th. Barclays cut their price objective on shares of Zoetis from $136.00 to $85.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 1st. Finally, Argus reiterated a “hold” rating on shares of Zoetis in a research report on Wednesday, May 27th. Eight analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Zoetis presently has a consensus rating of “Hold” and a consensus price target of $118.33.

Zoetis Price Performance

Shares of Zoetis stock opened at $77.37 on Friday. The business has a 50 day moving average of $77.05 and a 200 day moving average of $102.49. Zoetis Inc. has a 52 week low of $71.47 and a 52 week high of $160.48. The company has a market cap of $32.44 billion, a PE ratio of 12.83, a P/E/G ratio of 1.21 and a beta of 0.75. The company has a quick ratio of 1.91, a current ratio of 3.15 and a debt-to-equity ratio of 2.80.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.60 by ($0.07). The company had revenue of $2.26 billion during the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The business’s revenue was up 2.9% on a year-over-year basis. During the same quarter last year, the firm earned $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, equities research analysts forecast that Zoetis Inc. will post 6.87 earnings per share for the current year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be paid a dividend of $0.53 per share. The ex-dividend date of this dividend is Monday, July 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.7%. Zoetis’s payout ratio is presently 35.16%.

Insider Activity at Zoetis

In related news, Director Michael B. Mccallister acquired 3,000 shares of the stock in a transaction on Monday, May 11th. The stock was acquired at an average cost of $77.76 per share, for a total transaction of $233,280.00. Following the completion of the acquisition, the director directly owned 24,524 shares of the company’s stock, valued at approximately $1,906,986.24. This represents a 13.94% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Frank A. Damelio acquired 6,650 shares of the business’s stock in a transaction on Wednesday, May 13th. The shares were purchased at an average cost of $75.39 per share, for a total transaction of $501,343.50. Following the completion of the transaction, the director owned 21,458 shares in the company, valued at approximately $1,617,718.62. This represents a 44.91% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased 11,650 shares of company stock worth $886,384 over the last 90 days. 0.22% of the stock is owned by company insiders.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.